Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells

Atherosclerosis

Volumn 232, Issue 1, 2014, Pages 156-164

  Batchuluun, Battsetseg ^a   Inoguchi, Toyoshi ^a,b   Sonoda, Noriyuki ^a,b   Sasaki, Shuji ^a   Inoue, Tomoaki ^a   Fujimura, Yoshinori ^b   Miura, Daisuke ^b   Takayanagi, Ryoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

AMPK; DAG; Endothelial cell; High glucose; Liraglutide; Metformin; Oxidative stress; PKC

Indexed keywords

DIACYLGLYCEROL; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIRAGLUTIDE; METFORMIN; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

AORTA; ARTICLE; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

AMPK; DAG; ENDOTHELIAL CELL; HIGH GLUCOSE; LIRAGLUTIDE; METFORMIN; OXIDATIVE STRESS; PKC;

ACRIDINES; AORTA; BINDING SITES; CELLS, CULTURED; DIGLYCERIDES; ENDOTHELIAL CELLS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; LUMINESCENCE; METFORMIN; NADPH OXIDASE; OXIDATIVE STRESS; PHOSPHORYLATION; PLASMIDS; PROTEIN KINASE C; PROTEIN KINASE C BETA; REACTIVE OXYGEN SPECIES;

EID: 84891591832     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.10.025     Document Type: Article

References (42)

1. American Diabetes Association Consensus statement: role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 1993, 16:72-78.
2. Members A.T.F., Ryden L., Standl E., et al. Guidelines on diabetes, pre-diabetes, and cardiovascular disease. Eur Heart J Suppl 2007, 9(Suppl.C):C3-C74.
3. Hunt J.V., Dean R.T., Wolff S.P. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochem J 1988, 256:205-212.
4. Nishikawa T., Edelstein D., Du X.L., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
5. Inoguchi T., Li P., Umeda F., et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000, 49:1939-1945.
6. Inoguchi T., Sonta T., Tsubouchi H., et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. JAm Soc Nephrol 2003, 14:S227-S232.
7. Kim Y.K., Lee M.S., Son S.M., et al. Vascular NADH oxidase is involved in impaired endothelium-dependent vasodilation in OLETF rats, a model of type 2 diabetes. Diabetes 2002, 51:522-527.
8. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
9. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
10. Gallo A., Ceolotto G., Pinton P., et al. Metformin prevents glucose-induced protein kinase C-beta2 activation in human umbilical vein endothelial cells through an antioxidant mechanism. Diabetes 2005, 54:1123-1131.
11. Ouslimani N., Peynet J., Bonnefont-Rousselot D., et al. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metabolism 2005, 54:829-834.
12. Lovshin J.A., Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009, 5:262-269.
13. Fadini G.P., Simioni N., Frison V., et al. Independent glucose and weight-reducing effects of liraglutide in a real-world population of type 2 diabetic outpatients. Acta Diabetol 2013, 10.1007/s00592-013-0489-3.
14. Fadini G.P., Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol 2011, 55(1-3):10-16.
15. Nagashima M., Watanabe T., Terasaki M., et al. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 2011, 54:2649-2659.
16. Arakawa M., Mita T., Azuma K., et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010, 59:1030-1037.
17. Koska J., Schwartz E.A., Mullin M.P., et al. Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care 2010, 33:1028-1030.
18. Shiraki A., Oyama J., Komoda H., et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 2012, 221:375-382.
19. Rosse C., Linch M., Kermorgant S., et al. PKC and the control of localized signal dynamics. Nat Rev Mol Cell Biol 2010, 11:103-112.
20. Steinberg S.F. Structural basis of protein kinase C isoform function. Physiol Rev 2008, 88:1341-1378.
21. Folch J., Lees M., Sloane Stanley G.H. Asimple method for the isolation and purification of total lipides from animal tissues. JBiol Chem 1957, 226:497-509.
22. Bielawski J., Szulc Z.M., Hannun Y.A., et al. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 2006, 39:82-91.
23. Inoue T., Kobayashi K., Inoguchi T., et al. Reduced expression of adipose triglyceride lipase enhances tumor necrosis factor alpha-induced intercellular adhesion molecule-1 expression in human aortic endothelial cells via protein kinase C-dependent activation of nuclear factor-kappaB. JBiol Chem 2011, 286:32045-32053.
24. Fujii M., Inoguchi T., Sasaki S., et al. Bilirubin and biliverdin protect rodents against diabetic nephropathy by downregulating NAD(P)H oxidase. Kidney Int 2010, 78:905-919.
25. Inoguchi T., Battan R., Handler E., et al. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A 1992, 89:11059-11063.
26. Ishi H. Amelioration of vascular dysfunction in diabetic rats by an oral PKC beta inhibitor. Science 1996, 272:728-731.
27. Tabit C.E., Shenouda S.M., Holbrook M., et al. Protein kinase C-β contributes to impaired endothelial insulin signaling in humans with diabetes mellitus. Circulation 2013, 127:86-95.
28. Kouroedov A., Eto M., Joch H., et al. Selective inhibition of protein kinase C b 2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells. Circ J 2004, 110:91-96.
29. Geraldes P., King G.L. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010, 106:1319-1331.
30. Khankoeva A., Dukhanin A., Galeno-Yaroshevskii P. Mechanism of histamine-induced increase of calcium level in cardiomyocytes. A relative efficacy of histamine receptor blockers. Bull Exp Biol Med 1997, 123(4):357-359.
31. Schaefer M., Albrecht N., Hofmann T., Gudermann T., Schultz G. Diffusion-limited translocation mechanism of protein kinase C isotypes. FASEB J 2001 Jul, 15(9):1634-1636.
32. Ido Y., Carling D., Ruderman N. Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes 2002, 51:159-167.
33. Inoguchi T., Pu X., Kunisaki M., et al. Insulin's effect on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues. Am J Physiol 1994, 267:369-379.
34. Pu X., Inoguchi T., Kern T.S., et al. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C in diabetes and hypergalactosemia. Diabetes 1994, 43:1122-1129.
35. Ruderman N.B., Saha A.K., Kraegen E.W. Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity. Endocrinol 2003, 144:5166-5171.
36. Kraegen E.W., Saha A.K., Preston E., et al. Increased malonyl-CoA and diacylglycerol content and reduced AMPK activity accompany insulin resistance induced by glucose infusion in muscle and liver of rats. Am J Physiol Endocrinol Metab 2006, 290:E471-E479.
37. Carling D., Mayer F.V., Sanders M.J., et al. AMP-activated protein kinase: nature's energy sensor. Nat Chem Biol 2011, 7:512-518.
38. Schimmack G., Defronzo R.A., Musi N. AMP-activated protein kinase: role in metabolism and therapeutic implications. Diabetes Obes Metab 2006, 8:591-602.
39. Luo G., Kong X., Lu L., et al. Glucagon-like peptide 1 potentiates glucotoxicity-diminished insulin secretion via stimulation of cAMP-PKA signaling in INS-1E cells and mouse islets. Int J Biochem Cell Biol 2013, 45:483-490.
40. Yin W., Mu J., Birnbaum M.J. Role of AMP-activated protein kinase in cyclic AMP dependent lipolysis in 3T3-L1 adipocytes. JBiol Chem 2003, 278:43074-43080.
41. Park S.J., Ahmad F., Philp A., et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012, 148:421-433.
42. Mima A., Hiraoka-Yamomoto J., Li Q., et al. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes. Diabetes 2012, 61:2967-2979.